🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's series of deals with Washington are "built on sand." This stems from revelations that a so-called "milestone" deal on medicines, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond vague headline terms published in government press releases.

Lacking Legal Footing

The arrangement concerning medicines, hailed as a "significant" achievement, is still an "statement of intent" without detailed provisions. Critics have noted that the official announcements from the UK and US governments frame the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement highlights the commitment for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has made commitments to increase medicine costs in return for only a pledge from President Trump," commented David Henig, a trade policy analyst. "It is documented he has form for not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Worries have been heightened by Washington's move to suspend the high-value digital accord, which was previously heralded as "a generational step-change" in the bilateral relationship. The US pointed to a lack of progress from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions agreed to for British farmers as part of an initial accord have yet to be formally approved by the US, despite a imminent January deadline. "It is our belief that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Privately, ministers have voiced worries that the government's agreements with the US are lacking substance. One minister described the series of agreements as "resting on shaky ground," while another characterized the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than the administration's tactics is the UK government's naive belief that his administration is a good faith actor. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Officials have attempted to minimize the chances of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that volatility is a feature of dealing with the Trump administration. However, they argue that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

However, problems have emerged in implementing the broader trade deal. Promised quotas on beef exports have yet to be finalized, and the pledge to "remove tariffs on British steel and aluminium" has is still pending, with tariffs remaining at 25%.

Looking ahead, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.